Lymphoma Clinical Trials in Phoenix

Showing 241-247 of 247 trials

Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

NCT00955786

This phase 1 study of CX-3543 is designed to test the safety, tolerability and highest safe dose level of this drug in patients with advanced solid tumor cancers.

Advanced Solid TumorsLymphoma

Cylene Pharmaceuticals48 participantsStarted Jul 2005

Scottsdale, Arizona, United States • San Antonio, Texas, United States

UNKNOWNPHASE1108 miles

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

NCT00053105

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effect of combination chemotherapy on the body when treating patients who have relapsed or refractory aggressive non-Hodgkin's lymphoma.

Lymphoma

TheradexStarted Feb 2002

Tucson, Arizona, United States • Springdale, Arkansas, United States • Los Angeles, California, United States +4 more locations

COMPLETEDPHASE2251 miles

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00090090

To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).

Mantle Cell LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Spectrum Pharmaceuticals, Inc114 participantsStarted Apr 2004

Berkeley, California, United States • Burbank, California, United States • Los Angeles, California, United States +4 more locations

Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma Trials in Other Cities

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Other Conditions in Phoenix